-+ 0.00%
-+ 0.00%
-+ 0.00%

Baird Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $90

Benzinga·09/18/2026 11:07:35
Listen to the news
Baird analyst Brian Skorney maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and lowers the price target from $97 to $90.